Prevention of lyme disease

Neal A Halsey, J. S. Abramson, P. J. Chesney, M. C. Fisher, M. A. Gerber, S. M. Marcy, D. L. Murray, G. D. Overturf, C. G. Prober, T. N. Saari, L. B. Weiner, R. J. Whitley

Research output: Contribution to journalArticle

Abstract

Lyme disease is currently the most frequently reported vector-borne illness in the United States, accounting for more than 95% of such cases. The purpose of this report is to provide recommendations for preventing Lyme disease, including the use of Lyme disease vaccine. Individuals can reduce their risk of Lyme disease by avoiding tick-infested habitats when in endemic areas. If exposure to tick-infested habitats cannot be avoided, individuals may reduce their risk of infection by using repellents, wearing protective clothing, and regularly checking for and removing attached ticks. Morbidity from Lyme disease can be reduced significantly by detecting and treating the infection in its early stages; early and appropriate treatment almost always results in a prompt and uncomplicated cure. A Lyme disease vaccine (LYMErix, SmithKline Beecham, Collegeville, PA) was licensed by the US Food and Drug Administration on December 21, 1998, for persons 15 to 70 years of age. This vaccine seems to be safe and effective, but whether its use is cost-effective has yet to be clearly established. Use of this vaccine causes false-positive enzyme immunoassay results for Lyme disease. Lyme disease can be diagnosed in vaccinated persons by immunoblot testing. Decisions about the use of this vaccine should be based on an assessment of a person's risk as determined by activities and behaviors relating to tick exposure in endemic areas. This vaccine should be considered an adjunct to, not a replacement for, the practice of personal protective measures against tick exposure and the early diagnosis and treatment of Lyme disease.

Original languageEnglish (US)
Pages (from-to)142-147
Number of pages6
JournalPediatrics
Volume105
Issue number1 I
StatePublished - Jan 2000
Externally publishedYes

Fingerprint

Lyme Disease
Ticks
Lyme Disease Vaccines
Vaccines
Ecosystem
Protective Clothing
United States Food and Drug Administration
Infection
Immunoenzyme Techniques
Early Diagnosis
Morbidity
Costs and Cost Analysis
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Halsey, N. A., Abramson, J. S., Chesney, P. J., Fisher, M. C., Gerber, M. A., Marcy, S. M., ... Whitley, R. J. (2000). Prevention of lyme disease. Pediatrics, 105(1 I), 142-147.

Prevention of lyme disease. / Halsey, Neal A; Abramson, J. S.; Chesney, P. J.; Fisher, M. C.; Gerber, M. A.; Marcy, S. M.; Murray, D. L.; Overturf, G. D.; Prober, C. G.; Saari, T. N.; Weiner, L. B.; Whitley, R. J.

In: Pediatrics, Vol. 105, No. 1 I, 01.2000, p. 142-147.

Research output: Contribution to journalArticle

Halsey, NA, Abramson, JS, Chesney, PJ, Fisher, MC, Gerber, MA, Marcy, SM, Murray, DL, Overturf, GD, Prober, CG, Saari, TN, Weiner, LB & Whitley, RJ 2000, 'Prevention of lyme disease', Pediatrics, vol. 105, no. 1 I, pp. 142-147.
Halsey NA, Abramson JS, Chesney PJ, Fisher MC, Gerber MA, Marcy SM et al. Prevention of lyme disease. Pediatrics. 2000 Jan;105(1 I):142-147.
Halsey, Neal A ; Abramson, J. S. ; Chesney, P. J. ; Fisher, M. C. ; Gerber, M. A. ; Marcy, S. M. ; Murray, D. L. ; Overturf, G. D. ; Prober, C. G. ; Saari, T. N. ; Weiner, L. B. ; Whitley, R. J. / Prevention of lyme disease. In: Pediatrics. 2000 ; Vol. 105, No. 1 I. pp. 142-147.
@article{5d5de343417c4608b86a0c32ac1ff35b,
title = "Prevention of lyme disease",
abstract = "Lyme disease is currently the most frequently reported vector-borne illness in the United States, accounting for more than 95{\%} of such cases. The purpose of this report is to provide recommendations for preventing Lyme disease, including the use of Lyme disease vaccine. Individuals can reduce their risk of Lyme disease by avoiding tick-infested habitats when in endemic areas. If exposure to tick-infested habitats cannot be avoided, individuals may reduce their risk of infection by using repellents, wearing protective clothing, and regularly checking for and removing attached ticks. Morbidity from Lyme disease can be reduced significantly by detecting and treating the infection in its early stages; early and appropriate treatment almost always results in a prompt and uncomplicated cure. A Lyme disease vaccine (LYMErix, SmithKline Beecham, Collegeville, PA) was licensed by the US Food and Drug Administration on December 21, 1998, for persons 15 to 70 years of age. This vaccine seems to be safe and effective, but whether its use is cost-effective has yet to be clearly established. Use of this vaccine causes false-positive enzyme immunoassay results for Lyme disease. Lyme disease can be diagnosed in vaccinated persons by immunoblot testing. Decisions about the use of this vaccine should be based on an assessment of a person's risk as determined by activities and behaviors relating to tick exposure in endemic areas. This vaccine should be considered an adjunct to, not a replacement for, the practice of personal protective measures against tick exposure and the early diagnosis and treatment of Lyme disease.",
author = "Halsey, {Neal A} and Abramson, {J. S.} and Chesney, {P. J.} and Fisher, {M. C.} and Gerber, {M. A.} and Marcy, {S. M.} and Murray, {D. L.} and Overturf, {G. D.} and Prober, {C. G.} and Saari, {T. N.} and Weiner, {L. B.} and Whitley, {R. J.}",
year = "2000",
month = "1",
language = "English (US)",
volume = "105",
pages = "142--147",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "1 I",

}

TY - JOUR

T1 - Prevention of lyme disease

AU - Halsey, Neal A

AU - Abramson, J. S.

AU - Chesney, P. J.

AU - Fisher, M. C.

AU - Gerber, M. A.

AU - Marcy, S. M.

AU - Murray, D. L.

AU - Overturf, G. D.

AU - Prober, C. G.

AU - Saari, T. N.

AU - Weiner, L. B.

AU - Whitley, R. J.

PY - 2000/1

Y1 - 2000/1

N2 - Lyme disease is currently the most frequently reported vector-borne illness in the United States, accounting for more than 95% of such cases. The purpose of this report is to provide recommendations for preventing Lyme disease, including the use of Lyme disease vaccine. Individuals can reduce their risk of Lyme disease by avoiding tick-infested habitats when in endemic areas. If exposure to tick-infested habitats cannot be avoided, individuals may reduce their risk of infection by using repellents, wearing protective clothing, and regularly checking for and removing attached ticks. Morbidity from Lyme disease can be reduced significantly by detecting and treating the infection in its early stages; early and appropriate treatment almost always results in a prompt and uncomplicated cure. A Lyme disease vaccine (LYMErix, SmithKline Beecham, Collegeville, PA) was licensed by the US Food and Drug Administration on December 21, 1998, for persons 15 to 70 years of age. This vaccine seems to be safe and effective, but whether its use is cost-effective has yet to be clearly established. Use of this vaccine causes false-positive enzyme immunoassay results for Lyme disease. Lyme disease can be diagnosed in vaccinated persons by immunoblot testing. Decisions about the use of this vaccine should be based on an assessment of a person's risk as determined by activities and behaviors relating to tick exposure in endemic areas. This vaccine should be considered an adjunct to, not a replacement for, the practice of personal protective measures against tick exposure and the early diagnosis and treatment of Lyme disease.

AB - Lyme disease is currently the most frequently reported vector-borne illness in the United States, accounting for more than 95% of such cases. The purpose of this report is to provide recommendations for preventing Lyme disease, including the use of Lyme disease vaccine. Individuals can reduce their risk of Lyme disease by avoiding tick-infested habitats when in endemic areas. If exposure to tick-infested habitats cannot be avoided, individuals may reduce their risk of infection by using repellents, wearing protective clothing, and regularly checking for and removing attached ticks. Morbidity from Lyme disease can be reduced significantly by detecting and treating the infection in its early stages; early and appropriate treatment almost always results in a prompt and uncomplicated cure. A Lyme disease vaccine (LYMErix, SmithKline Beecham, Collegeville, PA) was licensed by the US Food and Drug Administration on December 21, 1998, for persons 15 to 70 years of age. This vaccine seems to be safe and effective, but whether its use is cost-effective has yet to be clearly established. Use of this vaccine causes false-positive enzyme immunoassay results for Lyme disease. Lyme disease can be diagnosed in vaccinated persons by immunoblot testing. Decisions about the use of this vaccine should be based on an assessment of a person's risk as determined by activities and behaviors relating to tick exposure in endemic areas. This vaccine should be considered an adjunct to, not a replacement for, the practice of personal protective measures against tick exposure and the early diagnosis and treatment of Lyme disease.

UR - http://www.scopus.com/inward/record.url?scp=0033971395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033971395&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033971395

VL - 105

SP - 142

EP - 147

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 1 I

ER -